Co-Diagnostics logo
Co-Diagnostics CODX

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Co-Diagnostics Financial Ratios 2011-2026 | CODX

Annual Financial Ratios Co-Diagnostics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-1.0 -6.6 7.0 8.5 -7.3 -4.5 -4.6 - - - - - -

P/S

5.1 2.7 2.6 4.8 210.5 700.7 4191.3 - - - - - -

EPS

-1.2 -0.5 1.3 1.6 -0.4 -0.5 -0.6 - - - - - -

EV (Enterprise Value)

29.3 M 79.1 M 195 M 322 M 44.8 M 29.6 M 29.4 M 3.29 M 1.52 M - - - -

EBITDA per Share

-1.41 -0.82 1.61 1.49 -0.348 -0.486 -0.412 - - - - - -

EV/EBITDA

3.6 7.6 -7.6 -4.8 -6.3 - - - - - -

PEG

0.01 0.05 - 0.01 -0.26 -0.22 0.02 - - - - - -

P/B

0.4 0.8 1.9 5.4 26.0 -26.4 8.3 - - - - - -

P/CF

-1.6 14.2 6.3 13.2 -8.0 -6.8 -9.6 - - - - - -

ROE %

-41.08 -12.43 27.26 63.69 -356.63 592.34 -180.73 - - - - - -

ROA %

-37.07 -11.57 22.91 59.63 -279.67 -403.80 -149.27 - - - - - -

ROCE %

-47.68 -22.63 31.24 62.48 -312.29 765.87 -113.14 - - - - - -

Current Ratio

10.2 14.4 6.3 15.2 4.8 0.4 7.1 - - - - - -

DSO

100.7 129.6 61.5 59.4 223.1 122.7 - - - - - - -

DIO

304.2 243.6 157.7 175.9 640.1 705.6 10959.7 - - - - - -

DPO

106.2 51.9 19.0 13.2 19.3 5789.9 49334.2 - - - - - -

Operating Cycle

404.9 373.1 219.1 235.3 863.2 828.3 10959.7 - - - - - -

Cash Conversion Cycle

298.7 321.2 200.1 222.1 843.8 -4961.6 -38374.6 - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Co-Diagnostics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.16 -0.23 -0.24 - -0.32 -0.25 -0.31 - -0.2 -0.31 -0.2 - -0.04 -0.08 0.35 - 0.4 0.34 0.28 - 0.56 0.54 -0.05 - -0.1 -0.08 -0.09 - -0.13 -0.11 -0.11 - -0.33 - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.18 -0.23 -0.26 - -0.32 -0.24 -0.33 - -0.29 -0.4 -0.33 - -0.2 -0.11 0.3 - 0.48 0.41 0.36 - 0.43 0.53 -0.05 - -0.09 -0.08 -0.08 - -0.13 -0.11 -0.1 - -0.15 -0.07 -0.06 - -0.04 -0.04 - - - - - - - - - - - - - - - - - - - - -

ROE %

-64.49 -64.91 -56.62 -37.58 -43.60 -34.41 -32.53 -19.84 -20.85 -15.84 -9.08 5.06 16.52 28.99 42.06 33.03 56.62 68.74 80.03 44.49 -56.12 -180.31 -280.19 -256.76 -101.76 153.84 360.83 408.34 307.22 51.11 -100.69 -141.65 -126.62 -10.48 26.50 29.81 29.81 14.78 - - - - - - - - - - - - - - - - - - - - -

ROA %

-56.85 -57.09 -49.87 -22.81 -28.32 -20.43 -18.92 -18.33 -19.25 -14.67 -8.43 4.25 15.15 26.96 39.17 31.18 53.26 64.45 74.97 41.65 -37.24 -138.22 -219.97 -201.35 -307.01 -333.78 -361.44 -278.37 -361.88 -339.73 -269.72 -116.99 -151.71 -102.92 -118.74 -68.88 -68.88 -34.16 - - - - - - - - - - - - - - - - - - - - -

ROCE %

-68.49 -66.77 -58.11 -25.56 -34.18 -27.44 -28.39 -28.54 -33.15 -29.13 -20.68 -1.09 12.38 30.45 46.53 40.31 58.35 62.93 71.58 38.46 -48.05 -152.61 -245.15 -223.49 -15.21 279.59 519.51 537.62 497.63 249.36 63.99 -68.78 -53.39 1.98 33.24 30.70 30.70 15.31 - - - - - - - - - - - - - - - - - - - - -

Current Ratio

9.1 8.7 7.6 6.6 8.4 9.7 - 10.2 11.8 12.0 18.4 14.4 11.5 9.8 7.3 6.3 20.3 16.8 16.7 15.7 15.7 15.7 15.7 4.6 4.6 4.6 4.6 0.6 0.6 0.6 0.6 5.7 5.7 5.7 5.7 0.3 0.3 0.3 - - - - - - - - - - - - - - - - - - - - -

DSO

83.8 97.3 244.1 - 51.9 - - - 35.4 876.4 466.6 - 181.1 308.1 85.4 - 41.5 41.5 55.3 - 50.8 46.1 361.5 - 289.3 194.7 1943.1 - 126.3 126.3 63.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

3774.6 3080.8 4556.2 - 418.8 - - - 1643.2 992.4 963.4 - 602.9 478.8 96.0 - 102.3 188.0 197.9 - 125.3 122.1 775.9 - 883.5 463.6 21734.6 - - - - - 2739.9 2739.9 - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

5369.8 6178.6 12694.0 - 619.8 - - - 558.1 252.6 161.9 - 172.6 102.8 25.3 - 16.9 19.9 17.6 - 9.4 9.1 57.2 - 26.7 14.0 15638.3 - - - - - 12333.6 12333.6 - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

3858.3 3178.1 4800.3 - 470.7 - - - 1678.5 1868.8 1430.0 - 784.0 786.9 181.4 - 143.7 229.5 253.1 - 176.1 168.2 1137.3 - 1172.8 658.3 23677.7 - 126.3 126.3 63.1 - 2739.9 2739.9 - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

-1511.5 -3000.5 -7893.8 - -149.0 - - - 1120.4 1616.2 1268.1 - 611.5 684.1 156.1 - 126.8 209.5 235.5 - 166.7 159.0 1080.1 - 1146.1 644.3 8039.4 - 126.3 126.3 63.1 - -9593.6 -9593.6 - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Co-Diagnostics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.83 -4.39 % $ 91.8 K usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Agilent Technologies Agilent Technologies
A
$ 115.87 -1.95 % $ 35.2 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 27.47 -1.86 % $ 763 M usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 13.81 -2.78 % $ 418 M usaUSA
Celcuity Celcuity
CELC
$ 105.83 -2.29 % $ 4.17 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 105.3 -2.75 % $ 8.69 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 642.42 0.9 % $ 51.7 B usaUSA
Illumina Illumina
ILMN
$ 128.6 -3.23 % $ 20.4 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Charles River Laboratories International Charles River Laboratories International
CRL
$ 174.83 -2.12 % $ 8.67 B usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 280.01 -2.26 % $ 23.3 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 77.75 1.9 % $ 5.25 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 303.47 -1.63 % $ 26.9 B schweizSchweiz
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Myriad Genetics Myriad Genetics
MYGN
$ 4.96 -1.0 % $ 459 M usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
NeoGenomics NeoGenomics
NEO
$ 9.08 -4.42 % $ 1.16 B usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Natera Natera
NTRA
$ 198.57 -0.8 % $ 19.5 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.51 -7.1 % $ 453 M usaUSA
Biodesix Biodesix
BDSX
$ 15.96 1.33 % $ 2.07 B usaUSA
Precipio Precipio
PRPO
$ 24.47 -0.85 % $ 31.8 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.09 -4.17 % $ 1.39 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 205.94 -2.05 % $ 22.9 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 201.72 -2.03 % $ 144 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 7.65 -7.64 % $ 319 M usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 15.56 -2.16 % $ 4.42 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 37.76 -3.33 % $ 1.92 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 103.23 -0.12 % $ 19.5 B usaUSA
Bioventus Bioventus
BVS
$ 8.69 -0.91 % $ 544 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 10.55 -1.86 % $ 299 M israelIsrael
DexCom DexCom
DXCM
$ 73.46 -0.43 % $ 28.7 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 501.43 -1.38 % $ 189 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 24.2 -3.82 % $ 258 M chinaChina
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 44.79 -2.4 % $ 2.68 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 18.19 -2.96 % $ 969 M usaUSA
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.2 -3.15 % $ 19.2 M singaporeSingapore
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Waters Corporation Waters Corporation
WAT
$ 306.49 -0.21 % $ 18.3 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Guardant Health Guardant Health
GH
$ 90.69 -1.67 % $ 11.4 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 171.73 -1.46 % $ 29.5 B usaUSA